Hammer M - Search Results

1

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Sullivan SD, et al. Among authors: hammer m. Cardiovasc Diabetol. 2009 Feb 26;8:12. doi: 10.1186/1475-2840-8-12. Cardiovasc Diabetol. 2009. PMID: 19245711 Free PMC article. Clinical Trial.

2

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.

Lee WC, Conner C, Hammer M. Lee WC, et al. Among authors: hammer m. Curr Med Res Opin. 2011 May;27(5):897-906. doi: 10.1185/03007995.2011.559444. Epub 2011 Feb 25. Curr Med Res Opin. 2011. PMID: 21348806 Clinical Trial.

3

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Sullivan SD, et al. Among authors: hammer m. Pharmacotherapy. 2009 Nov;29(11):1280-8. doi: 10.1592/phco.29.11.1280. Pharmacotherapy. 2009. PMID: 19873688 Clinical Trial.

4

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Among authors: hammer m. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.

5

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.

Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D. Hermansen K, et al. Among authors: hammer m. Prim Care Diabetes. 2010 Jul;4(2):113-7. doi: 10.1016/j.pcd.2010.04.001. Epub 2010 May 4. Prim Care Diabetes. 2010. PMID: 20444662 Clinical Trial.

6

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.

Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Schmidt WE, et al. Among authors: hammer m. Diabet Med. 2011 Jun;28(6):715-23. doi: 10.1111/j.1464-5491.2011.03276.x. Diabet Med. 2011. PMID: 21388442 Free PMC article. Clinical Trial.

7

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.

Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Davies M, et al. Among authors: hammer m. Diabet Med. 2011 Mar;28(3):333-7. doi: 10.1111/j.1464-5491.2010.03074.x. Diabet Med. 2011. PMID: 21309842 Clinical Trial.

8

Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.

Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S. Horowitz M, et al. Among authors: hammer m. Diabetes Obes Metab. 2008 Jul;10(7):593-6. doi: 10.1111/j.1463-1326.2008.00861.x. Epub 2008 Apr 22. Diabetes Obes Metab. 2008. PMID: 18435773 Clinical Trial. No abstract available.

9

Exposure to emissions generated by 3-dimensional printing with polycarbonate: effects on peripheral vascular function, cardiac vascular morphology and expression of markers of oxidative stress in male rat cardiac tissue.

Krajnak K, Farcas M, Richardson D, Hammer MA, Waugh S, McKinney W, Knepp A, Jackson M, Burns D, LeBouf R, Matheson J, Thomas T, Qian Y. Krajnak K, et al. Among authors: hammer ma. J Toxicol Environ Health A. 2024 Apr 29:1-19. doi: 10.1080/15287394.2024.2346938. Online ahead of print. J Toxicol Environ Health A. 2024. PMID: 38682597

10

Neurodegenerative disease pathways are perturbed in patients with cancer who self-report cognitive changes and anxiety: A pathway impact analysis.

Oppegaard KR, Mayo SJ, Armstrong TS, Dokiparthi V, Melisko M, Levine JD, Olshen AB, Anguera JA, Roy R, Paul S, Cooper B, Conley YP, Hammer MJ, Miaskowski C, Kober KM. Oppegaard KR, et al. Among authors: hammer mj. Cancer. 2024 Apr 27. doi: 10.1002/cncr.35336. Online ahead of print. Cancer. 2024. PMID: 38676932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,309 results

Search Page